Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Phase III
Biotech
KalVista's persistence with sebetralstat pays off in ph. 3 win
KalVista's oral HAE treatment was found to hasten the time to symptom remedy by roughly four hours compared to placebo.
Max Bayer
Feb 13, 2024 6:30am
Merck KGaA tacks on Abbisko’s joint tumor med for $70M upfront
Dec 4, 2023 10:26am
Deciphera's tumor-tackling oral med achieves 40% response rate
Oct 30, 2023 11:00am
Relmada's depression med bounces back in open-label trial
Sep 20, 2023 11:00am
Pfizer steers group B strep vax to ph. 3 immunogenicity study
Aug 24, 2023 11:45am
Vistagen stock soars 1,272% on social anxiety spray data
Aug 7, 2023 11:38am